Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
63.3M
-
Shares change
-
+647K
-
Total reported value, excl. options
-
$912M
-
Value change
-
+$3.33M
-
Put/Call ratio
-
0.44
-
Number of buys
-
63
-
Number of sells
-
-48
-
Price
-
$14.42
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q1 2023
144 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.3M shares
of 89.6M outstanding shares and own 70.61% of the company stock.
Largest 10 shareholders include Alphabet Inc. (10.5M shares), FMR LLC (6.83M shares), ARK Investment Management LLC (4.48M shares), VANGUARD GROUP INC (3.88M shares), BlackRock Inc. (3.55M shares), STATE STREET CORP (3.35M shares), FEDERATED HERMES, INC. (2.4M shares), Casdin Capital, LLC (2.12M shares), ARCH Venture Management, LLC (2.01M shares), and T. Rowe Price Investment Management, Inc. (2.01M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.